Recombinant Human Granulocyte Stimulating Factor Injection, which stimulates the growth of human granulocytes, is used for various causes of neutropenia; to promote the elevation of neutrophils after bone marrow transplantation; and to prevent the occurrence of neutropenia. Side effects such as fatigue, bone pain, headache, rash, fever, elevated gammaglutaminase, and shock may occur. The drug should be used 24~48 hours after the end of chemotherapy, and the blood should be checked twice a week during the use of the drug. Drug interactions with lithium and other leukocyte-releasing drugs may occur, so you should consult a medical professional before use. Contraindicated in the following conditions: severe hepatic, renal, cardiac and pulmonary insufficiency; myelogenous leukemia in which naïve granulocytes are detected in the peripheral blood or in which naïve granulocytes in the bone marrow have not been significantly reduced; allergy to the drug and to other E. coli expressed preparations. Use with caution in pediatric patients; use with caution in patients with malignant proliferation of myeloid cell systems such as acute granulocytic leukemia. The drug may be secreted through breast milk and may affect the embryo, so the use of the drug in lactating women, pregnant women and women who may become pregnant should be carefully considered. Nursing women should stop breastfeeding if using the drug. If you need to use the drug, please be sure to follow the doctor’s instructions strictly under the guidance of the medication, do not self-medication.